Akademska digitalna zbirka SLovenije - logo
VSE knjižnice (vzajemna bibliografsko-kataložna baza podatkov COBIB.SI)
  • Novosti v terapiji KVČB = Novel therapy of inflammatory bowel disease
    Ferkolj, Ivan
    The goal of an acute exacerbation of inflammatory bowel disease treatment is to induce remission and to maintain the remission. Therapy should begin with an assessment of disease localization, ... extent, severity and the response to prior treatments. Mild to moderately active disease should be treated with oral mesalazine 3 - 4,5 g daily, moderate to severe extensive colitis requirescorticosteroid therapy. Distal disease can be treated either with topical mesalazine or topical corticosteroids or a combination of both. Severeto fuldminante colitis requires hospitalization and parenteral administration of corticosteroids. For the maintenance of remission of ulcerative colitis we use 5 - ASA compounds (mesalazin 2 - 3 g daily). The medications which are used to treat an acute exacerbation of Crohn's disease are: 5 ASA (3 - 4,5 g daily), antibiotics, gluccocorticoids and nutritional therapy. An orally controlled-release preparation of budesonide at a dose of 9mg per day is a well-tolerated and effective therapy for active Crohns disease of the ileum and proximal colon. The development of novel, highly effective forms of therapy, such as infliximab, a monoclonal antibody against TNF alpha, has shown dramatic efficacy in the treatment of Crohns disease. Theefficacy of mesalazin or other 5-ASA compounds in maintaining remission or prevention of postoperative recurrence for patients with Crohns disease is notas effective as in ulcerative colitis, we use mesalazin and azatioprin.
    Vir: Interna medicina 2005 - novosti in aktualnosti : zbornik predavanj (Str. 99-103)
    Vrsta gradiva - prispevek na konferenci
    Leto - 2005
    Jezik - slovenski
    COBISS.SI-ID - 20192217

Vnos na polico